Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy—a representative sample survey in Germany-Reference-Cited by-同舟云学术

Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy—a representative sample survey in Germany

Published:2015-06-17 Issue:1 Volume:24 Page:367-376
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Link Hartmut, ,Nietsch J.,Kerkmann M.,Ortner P.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-015-2779-5.pdf

Reference39 articles.

1. Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32

2. Abdelsattar ZM, Reames BN, Regenbogen SE et al (2015) Critical evaluation of the scientific content in clinical practice guidelines. Cancer. 121(5):783–789

3. Bennett CL, Djulbegovic B, Norris LB et al (2013) Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 368:1131–1139

4. Bodey GP (2009) Fever and neutropenia: the early years. J Antimicrob Chemother 63:i3–i13

5. Boland GM, Chang GJ, Haynes AB et al (2013) Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer 119:1593–1601

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leitlinienadhärenz bei Anämiemanagement, Neutropenieprophylaxe, Osteoprotektion, Immunglobulinsubstitution und Antiemese;Die Onkologie;2024-06-17

2. Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors—a questionnaire study;Supportive Care in Cancer;2024-05-14

3. Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study;Journal of Modern Oncology;2024-02-21

4. Qualitätssicherung zur Diagnose und Therapie von Harnblasenkarzinomen 2023 (QS Harnblase);Forum;2023-12-14

5. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer;Supportive Care in Cancer;2023-09-20